As reported by Kirchberger et al. that MEK inhibition chemo-sensitized NRASG12D-mutated ALL cells to conventional therapeutic agents (i.e., DNR and dexamethasone) (Irving et al., 2016), we thus tested the MEK inhibition response among those NRASG12 mutants transformed Ba/F3 cells. This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.